Suppression of mammary tumors by oral administration of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil in SHN virgin mice.
Sakamoto
S
S
Medical Research Institute, Tokyo Medical and Dental University, Japan.
Mizuno
M
M
Kudo
H
H
Suzuki
S
S
Kasahara
N
N
Sugiura
Y
Y
Mori
T
T
Nagasawa
H
H
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D005260:Female; D005472:Fluorouracil / Q000097:blood; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000517:prevention & control*; D051379:Mice; D008815:Mice, Inbred Strains; D009929:Organ Size / Q000187:drug effects; D005641:Tegafur / Q000627:therapeutic use*; D013937:Thymidine Kinase / Q000037:antagonists & inhibitors; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors; D014498:Uracil / Q000097:blood / Q000627:therapeutic use*
D005641:Tegafur; D014498:Uracil; C025404:3-FT; D013940:Thymidylate Synthase; D013937:Thymidine Kinase; D005472:Fluorouracil